THERMO FISHER SCIENTIFIC INC. (TMO) Form 8-K — Oct 21, 2026
Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% year over year, with 6% organic growth, for the quarter ended September 26, 2026. GAAP diluted EPS grew 9% to $4.64 while adjusted EPS grew 15% to $6.68, with GAAP operating margin expanding to 18.6% from 17.4% a year ago. The company completed its previously announced microbiology business divestiture during the quarter, launched new products including the Orbitrap Isora mass spectrometer and Ion 560 Chip, and partnered with Mayo Clinic on the Precure proteomics initiative.
Key figures
- Eps
- 4.64
- Revenue
- 12137000000
- Guidance
- Updated 2026 financial guidance to be provided on the earnings conference call
- Net Income
- 1721000000
- Revenue Yoy
- 9%
- Total Assets
- 114233000000
- Cash Position
- 5461000000
- Adjusted eps
- 6.68
- Adjusted eps yoy
- 15%
- Free cash flow q3
- 2115000000
- Nine month revenue
- 35136000000
- Gaap diluted eps yoy
- 9%
- Gaap operating margin
- 18.6%
- Prior year q3 revenue
- 11122000000
- Organic revenue growth
- 6%
- Adjusted operating income
- 2968000000
- Adjusted operating margin
- 24.5%
- Prior year q3 adjusted eps
- 5.79
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.